Shukra Pharmaceuticals Complete Financial Statements

In FY2025, Shukra Pharmaceuticals (SHUKRAPHAR) reported revenue ₹8 Cr, net profit ₹2 Cr and EPS ₹0.05, with a net profit margin of 25.0% and ROE of 3.2%. Full financial statements from FY2015 to FY2025 (11 years) — income statement, balance sheet and cash flow in ₹ Crores. Download as Excel or CSV. For live price, earnings ratios and company overview, see SHUKRAPHAR company profile.

11 Years of Data
2025 - 2015

Complete Financial Data Export

Profitability Ratios

Net Profit Margin 25.00% 2025 data
EBITDA Margin 12.50% 2025 data
Operating Margin -7.00% 2025 data
Return on Assets 2.30% 2025 data
Return on Equity 3.17% 2025 data

Balance Sheet Ratios

Current Ratio 9.29 2025 data
Equity Ratio 72.41% 2025 data
Asset Turnover 0.09 2025 data

SHUKRAPHAR Revenue, Net Profit & EBITDA — Year-on-Year Growth

SHUKRAPHAR YoY (Dec 2024 vs Sept 2025) — revenue -33.3%, net profit -33.3%, EBITDA -80.0%, expenses -14.3%.

Revenue Growth
-33.3%
Year-over-Year
Net Profit Growth
-33.3%
Year-over-Year
EBITDA Growth
-80.0%
Year-over-Year
Expense Growth
-14.3%
Year-over-Year
Assets Growth
+11.5%
Year-over-Year
Equity Growth
+8.6%
Year-over-Year
Operating Cash Flow Growth
+260.0%
Year-over-Year
Financing Cash Flow Growth
-141.7%
Year-over-Year

SHUKRAPHAR Income Statement — Revenue, EBITDA & Net Profit

Shukra Pharmaceuticals revenue ₹8 Cr, EBITDA ₹1 Cr, net profit ₹2 Cr, EPS ₹0.05 (2025) — net profit margin 25.0%. Explore Shukra Pharmaceuticals intrinsic worth to estimate fundamental worth using multiple valuation models.

Periods ₹ Crores
Particulars Sept 2025 Mar 2025 Jun 2025 Dec 2025 Dec 2024
Revenue 8 15 7 40 12
Expenses 6 6 4 12 7
EBITDA 1 9 2 28 5
Operating Profit Margin % -7.00% 55.00% 24.00% 69.00% 37.00%
Depreciation 1 1 1 1 1
Interest 0 0 0 0 0
Profit Before Tax 0 8 1 27 4
Tax -2 2 0 7 1
Net Profit 2 5 1 20 3
Earnings Per Share (₹) 0.05 0.12 0.02 0.47 0.72

SHUKRAPHAR Balance Sheet — Assets, Liabilities & Shareholders' Equity

SHUKRAPHAR total assets ₹87 Cr, total equity ₹63 Cr, total liabilities ₹ Cr (2025) — ROE 3.2%.

Years Annual Data ₹ Crores
Particulars 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
ASSETS
Total Assets 87 78 75 35 36 34 28 24 19 17 18
Current Assets 65 56 53 16 16 15 11 8 7 6 7
Fixed Assets 19 20 20 18 18 17 16 14 10 10 10
Capital Work in Progress 2 2 2 2 2 2 2 2 2 2 2
Investments 0 0 0 0 0 0 0 0 0 0 0
Other Assets 65 56 53 16 16 15 11 8 7 6 7
LIABILITIES
Total Liabilities
Current Liabilities 7 6 7 6 13 11 9 6 3 3 4
Non-Current Liabilities
SHAREHOLDERS' EQUITY
Total Equity 63 58 25 16 16 15 15 15 15 14 14
Share Capital 44 11 4 2 2 2 2 2 2 2 2
Reserves & Surplus 19 47 21 15 14 14 14 13 13 13 12

SHUKRAPHAR Cash Flow Statement — Operating, Investing & Financing

Shukra Pharmaceuticals operating cash flow ₹8 Cr, investing ₹-1 Cr, financing ₹-5 Cr, net cash flow ₹2 Cr (2025).

Periods ₹ Crores
Particulars March 2025 March 2024 March 2023 March 2022 March 2021 March 2020 March 2019 March 2018 March 2017 March 2016 March 2015
Operating Activities 8 -5 3 8 1 1 0 1 0 3 -2
Investing Activities -1 -1 -4 -2 -2 -3 -3 -5 -1 0 1
Financing Activities -5 12 5 -7 2 2 2 4 0 -1 1
Net Cash Flow 2 6 4 0 0 0 0 -1 -1 1 0